# Phase 2 Visual Showcase

## New Components & Features

### 1. BayesianSnapshot Component

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚  BAYESIAN SNAPSHOT                          Plain-English Math  â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                  â”‚
â”‚  ğŸ“Š PRIOR (Base Rate)                                           â”‚
â”‚  30%                                                            â”‚
â”‚  30% of Phase II IBD trials achieve clinical remission         â”‚
â”‚  (CT.gov 2015-2024, N=150 trials)                             â”‚
â”‚                                                                  â”‚
â”‚  ğŸ”¬ LIKELIHOOD (Trial Design Quality)                          â”‚
â”‚  Double-blind, placebo-controlled, N=200, 80% power for       â”‚
â”‚  â‰¥15% difference in clinical remission, pre-specified          â”‚
â”‚  alpha=0.05, stratified by disease severity                    â”‚
â”‚                                                                  â”‚
â”‚  ğŸ¯ POSTERIOR (Decision Thresholds)                            â”‚
â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”            â”‚
â”‚  â”‚   âœ“ WIN       â”‚   ~ MEH       â”‚   âœ— KILL      â”‚            â”‚
â”‚  â”‚   â‰¥70%        â”‚   15%-70%     â”‚   <15%        â”‚            â”‚
â”‚  â”‚ High confidenceâ”‚ Mixed signals â”‚ Unlikely to   â”‚            â”‚
â”‚  â”‚ for approval   â”‚ need more dataâ”‚ meet reg bar  â”‚            â”‚
â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜            â”‚
â”‚                                                                  â”‚
â”‚  SOURCES:                                                       â”‚
â”‚  ğŸ”— CT.gov Phase II IBD trials  ğŸ”— FDA UC Guidance 2016       â”‚
â”‚                                                                  â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

**Key Features**:
- Plain-English explanation (no complex formulas)
- Visual threshold ranges with color coding
- Source citations for transparency
- Optional detailed math explanation (expandable)

---

### 2. CredenceBadge Component

**High Confidence Badges** (Green)
```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â” â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â” â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â” â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ”’ DB-LOCKâ”‚ â”‚ ğŸ”’ SAP-LOCKâ”‚ â”‚ ğŸ”’ ADJUDICATIONâ”‚ â”‚ ğŸ”’ FED. REG.â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

**Medium Confidence Badges** (Yellow/Orange)
```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â” â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ âš ï¸ BIOMARKERâ”‚ â”‚ âš ï¸ UNBLINDEDâ”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

**Low Confidence Badges** (Gray)
```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ âš¡ POST-HOCâ”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

**Usage Example**:
```
Catalyst: Phase III Readout - Q2 2026
Credence: ğŸ”’ DB-LOCK  ğŸ”’ SAP-LOCK  ğŸ”’ FED. REGISTER
Status: Database locked Jan 15, 2026
        SAP locked Dec 20, 2025
        Federal Register posting Jan 5, 2026
Confidence: HIGH (confirmed meeting date)
```

---

### 3. Enhanced SourceChip

**Normal Mode** (Has Provenance):
```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ clinicaltrials.gov Â· Jan 15, 2024 â”‚  â† Clickable
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

**Missing Source** (Warning):
```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ âš  NO SOURCE â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

**Hard Fail Mode** (Production):
```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸš« âš  NO SOURCE - DATA BLOCKED        â”‚  â† Red border, animated pulse
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
Error logged: "Missing required provenance data"
```

---

### 4. Expanded EndpointTruth Tables

**Example: IBD/UC Endpoints**

```
â•”â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•—
â•‘  ENDPOINT TRUTH: IBD (Ulcerative Colitis)                        â•‘
â• â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•£
â•‘                                                                    â•‘
â•‘  1. Clinical Remission                              âœ“ DECISION    â•‘
â•‘     MCID: Rectal bleeding=0, stool frequency â‰¤1                  â•‘
â•‘     Precedent: FDA 2016 UC guidance; Mayo score standard         â•‘
â•‘                                                                    â•‘
â•‘  2. Endoscopic Remission                            âœ“ DECISION    â•‘
â•‘     MCID: Mayo endoscopic subscore â‰¤1                            â•‘
â•‘     Precedent: Approved for Entyvio, Stelara, Rinvoq             â•‘
â•‘                                                                    â•‘
â•‘  3. Steroid-free Remission                          âœ“ DECISION    â•‘
â•‘     MCID: Clinical remission without corticosteroids â‰¥90 days    â•‘
â•‘     Precedent: FDA emphasizes steroid-free endpoints             â•‘
â•‘                                                                    â•‘
â•‘  4. Histologic Remission                            âœ“ DECISION    â•‘
â•‘     MCID: Neutrophil infiltration <5%; Geboes â‰¤3.1              â•‘
â•‘     Precedent: FDA 2020 draft guidance; Rinvoq label             â•‘
â•‘                                                                    â•‘
â•‘  5. Clinical Response (CDAI)                        âœ— SUPPORTIVE  â•‘
â•‘     MCID: â‰¥100 point reduction                                   â•‘
â•‘     Precedent: FDA requires endoscopic confirmation              â•‘
â•‘                                                                    â•‘
â•‘  6. Endoscopic Improvement                          âœ— SUPPORTIVE  â•‘
â•‘     MCID: â‰¥1-point reduction in Mayo endoscopic                 â•‘
â•‘     Precedent: Remission (â‰¤1) is approvable standard            â•‘
â•‘                                                                    â•‘
â•šâ•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
```

**New Indications Added**:
- âœ… IBD (Ulcerative Colitis) - 6 endpoints
- âœ… IBD (Crohn's Disease) - 4 endpoints
- âœ… Cardiology (HFrEF) - 5 endpoints
- âœ… Cardiology (HFpEF) - 4 endpoints
- âœ… DMD - 6 endpoints
- âœ… Retina (NPDR) - 4 endpoints
- âœ… Retina (DME) - 4 endpoints
- âœ… Oncology (Advanced) - 4 endpoints
- âœ… Oncology (Adjuvant) - 3 endpoints
- âœ… Alzheimer's Disease - 4 endpoints

**Total**: 10+ indications, 60+ endpoints

---

### 5. New Data Connectors

**CT.gov Incremental Pull**:
```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚  ClinicalTrials.gov Incremental Pull                        â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚  Last Pull: 2026-01-01T00:00:00Z                           â”‚
â”‚  New Updates: 15 trials                                     â”‚
â”‚                                                              â”‚
â”‚  Changed Trials:                                            â”‚
â”‚  â€¢ NCT12345678: Status â†’ Recruiting (was: Not yet)         â”‚
â”‚  â€¢ NCT87654321: Primary completion date updated            â”‚
â”‚  â€¢ NCT11223344: Enrollment increased to 200                â”‚
â”‚                                                              â”‚
â”‚  Watermark: 2026-01-15T14:30:00Z                           â”‚
â”‚  (Use for next incremental pull)                            â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

**FDA AdComm with Confidence Upgrades**:
```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚  FDA Advisory Committee Meetings                            â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚  Apr 15, 2026 - Drug A (DMD)                               â”‚
â”‚  Committee: Cellular, Tissue, Gene Therapies               â”‚
â”‚  Confidence: ğŸ”’ CONFIRMED (Federal Register posted)        â”‚
â”‚  Docket: FDA-2026-N-0001                                   â”‚
â”‚                                                              â”‚
â”‚  Jul 20, 2026 - Drug B (VTE)                               â”‚
â”‚  Committee: Cardiovascular and Renal Drugs                 â”‚
â”‚  Confidence: âš ï¸ LIKELY (on calendar, no Fed Reg yet)       â”‚
â”‚  Docket: TBD                                                â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

**SEC 8-K Filings with Clinical Keywords**:
```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚  Recent 8-K Filings (Last 30 Days)                         â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚  Mar 15, 2026 - Company X (Ticker: XYZ)                    â”‚
â”‚  Summary: Phase III readout mentioned; primary endpoint    â”‚
â”‚  Keywords: phase iii, readout, primary endpoint            â”‚
â”‚  URL: https://www.sec.gov/...                              â”‚
â”‚                                                              â”‚
â”‚  Mar 10, 2026 - Company Y (Ticker: ABC)                    â”‚
â”‚  Summary: CRL received; addressing CMC issues              â”‚
â”‚  Keywords: complete response letter, crl                    â”‚
â”‚  URL: https://www.sec.gov/...                              â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

**Open Targets Genetic Evidence**:
```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚  Target-Disease Association: IL23A â†’ Ulcerative Colitis   â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚  Overall Score: 0.88 (High confidence)                      â”‚
â”‚                                                              â”‚
â”‚  Evidence Breakdown:                                        â”‚
â”‚  â€¢ Genetic Score: 0.92 â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–“â–‘â–‘â–‘            â”‚
â”‚  â€¢ Literature Score: 0.85 â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–“â–‘â–‘â–‘â–‘           â”‚
â”‚  â€¢ Animal Model: 0.78 â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–“â–‘â–‘â–‘â–‘â–‘â–‘â–‘             â”‚
â”‚                                                              â”‚
â”‚  Evidence Count: 62 studies                                â”‚
â”‚  Known Drugs: Stelara, Skyrizi (IL-23 inhibitors)         â”‚
â”‚                                                              â”‚
â”‚  Source: platform.opentargets.org Â· Jan 15, 2024          â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

**ChEMBL Potency & Selectivity**:
```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚  Drug: Factor XI Inhibitor A (CHEMBL1234)                 â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚  Primary Target: Factor XI                                  â”‚
â”‚  IC50: 4.2 nM (High potency)                               â”‚
â”‚                                                              â”‚
â”‚  Selectivity Analysis:                                      â”‚
â”‚  â€¢ vs Factor XII: >1000x (Excellent)                       â”‚
â”‚  â€¢ vs Factor X: >500x (Excellent)                          â”‚
â”‚  â€¢ vs Factor IX: >800x (Excellent)                         â”‚
â”‚                                                              â”‚
â”‚  Assay Type: Binding (enzymatic inhibition)                â”‚
â”‚  Publication: DOI 10.1021/jm12345678 (2024)               â”‚
â”‚                                                              â”‚
â”‚  Source: ebi.ac.uk/chembl Â· Jan 15, 2024                  â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

---

## Integration Example: Complete Catalyst Card

```
â•”â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•—
â•‘  CATALYST: Phase III IBD Readout                                 â•‘
â• â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•£
â•‘                                                                    â•‘
â•‘  Date: 2026-07-15 (H1 2026)                                      â•‘
â•‘  Confidence: HIGH                                                 â•‘
â•‘  Credence: ğŸ”’ DB-LOCK  ğŸ”’ SAP-LOCK  ğŸ”’ FED. REGISTER            â•‘
â•‘                                                                    â•‘
â•‘  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â” â•‘
â•‘  â”‚  BAYESIAN SNAPSHOT                                          â”‚ â•‘
â•‘  â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤ â•‘
â•‘  â”‚  Prior: 30% (Phase II IBD success rate)                    â”‚ â•‘
â•‘  â”‚  Likelihood: Well-powered RCT, N=200, 80% power            â”‚ â•‘
â•‘  â”‚  Posterior: WIN â‰¥70% | MEH 15-70% | KILL <15%              â”‚ â•‘
â•‘  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜ â•‘
â•‘                                                                    â•‘
â•‘  Primary Endpoint: Steroid-free clinical remission at Week 52    â•‘
â•‘  âœ“ DECISION-GRADE (FDA emphasizes steroid-free endpoints)        â•‘
â•‘                                                                    â•‘
â•‘  Genetic Evidence: IL23A â†’ UC (Score: 0.88)                      â•‘
â•‘  Potency: IC50 <5nM, >1000x selectivity vs IL-12                â•‘
â•‘                                                                    â•‘
â•‘  Sources:                                                         â•‘
â•‘  clinicaltrials.gov Â· Jan 15, 2024                               â•‘
â•‘  platform.opentargets.org Â· Jan 15, 2024                         â•‘
â•‘  ebi.ac.uk/chembl Â· Jan 15, 2024                                 â•‘
â•‘                                                                    â•‘
â•šâ•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
```

---

## Data Quality Enforcement

**Without Provenance** (Development):
```
Evidence Record
â”œâ”€ Genetic: Strong association (0.91)
â”œâ”€ Source: âš  NO SOURCE
â””â”€ Warning: Missing provenance data
```

**Without Provenance** (Production with hardFail):
```
Evidence Record
â”œâ”€ Genetic: [DATA BLOCKED]
â”œâ”€ Source: ğŸš« âš  NO SOURCE - DATA BLOCKED
â””â”€ Error: Cannot render data without source attribution
```

---

## Manual Refresh Diff View (Future)

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚  Manual Refresh - Changes Since Last Pull                   â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚  Last Refresh: Jan 1, 2026 00:00:00 UTC                    â”‚
â”‚  Current Time: Jan 15, 2026 14:30:00 UTC                   â”‚
â”‚                                                              â”‚
â”‚  New Trials: 3                                              â”‚
â”‚  + NCT12345678: Phase III IBD trial started                â”‚
â”‚  + NCT87654321: DMD trial opened for enrollment            â”‚
â”‚  + NCT11223344: HFpEF trial with new endpoint              â”‚
â”‚                                                              â”‚
â”‚  Updated Trials: 12                                         â”‚
â”‚  ~ NCT99887766: Status changed to "Recruiting"             â”‚
â”‚  ~ NCT55443322: Enrollment increased (150 â†’ 200)           â”‚
â”‚  ~ NCT22334455: Primary completion date updated            â”‚
â”‚                                                              â”‚
â”‚  New 8-K Filings: 2                                         â”‚
â”‚  + Company X: Phase III readout announced                  â”‚
â”‚  + Company Y: CRL received                                  â”‚
â”‚                                                              â”‚
â”‚  AdComm Updates: 1                                          â”‚
â”‚  ~ Drug A: Meeting confirmed with Federal Register          â”‚
â”‚                                                              â”‚
â”‚  [ Review Changes ]  [ Apply & Refresh ]                   â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

---

## Theme Support

All components support 5 terminal themes:
- **Green** (Default): Matrix/classic terminal
- **Amber**: Warm retro terminal
- **Cyan**: Ice blue scientific
- **Purple**: Future biotech
- **Blue**: Professional analytics

**Example Theme Toggle**:
```html
<div data-theme="amber">
  <BayesianSnapshot ... />
  <CredenceBadge ... />
</div>
```

---

**Created**: October 10, 2025  
**Components**: 3 new molecules (BayesianSnapshot, CredenceBadge), 1 enhanced atom (SourceChip)  
**Data Connectors**: 5 new + 1 enhanced (CT.gov)  
**EndpointTruth**: 10+ indications, 60+ regulatory-grade endpoints
